COX-2 inhibitors act as radiosensitizer in tumor treatment

P. Sminia, G. Kuipers, A. Geldof, V. Lafleur, B. Slotman

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Since cyclooxygenase-2 (COX-2) is overexpressed in malignant tissues, the COX-2 mediated signaling pathway has been recognized as potential target for therapeutic intervention. In most human tumors, COX-2 overexpression has been associated with tumor aggressiveness and poor clinical outcome. In vitro studies show inhibition of cell proliferation by selective COX-2 inhibitors alone, and enhancement of the response to irradiation. In vivo experimental reports demonstrate enhanced tumor response and impediment of tumor neovascularization following radiotherapy combined with COX-2 inhibition. Clinical studies on the combination of irradiation with COX-2 inhibitors are emerging. Taken together, the perspective for the combined approach of radiotherapy with COX-2 inhibition yields clinical significance since preclinical data demonstrate selective COX-2 inhibitors to act as radiosensitizer in tumor treatment.

Original languageEnglish
JournalBiomedicine and Pharmacotherapy
Volume59
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 1 Oct 2005

Cite this

@article{95c965501bd24b2582638f9d887ba4af,
title = "COX-2 inhibitors act as radiosensitizer in tumor treatment",
abstract = "Since cyclooxygenase-2 (COX-2) is overexpressed in malignant tissues, the COX-2 mediated signaling pathway has been recognized as potential target for therapeutic intervention. In most human tumors, COX-2 overexpression has been associated with tumor aggressiveness and poor clinical outcome. In vitro studies show inhibition of cell proliferation by selective COX-2 inhibitors alone, and enhancement of the response to irradiation. In vivo experimental reports demonstrate enhanced tumor response and impediment of tumor neovascularization following radiotherapy combined with COX-2 inhibition. Clinical studies on the combination of irradiation with COX-2 inhibitors are emerging. Taken together, the perspective for the combined approach of radiotherapy with COX-2 inhibition yields clinical significance since preclinical data demonstrate selective COX-2 inhibitors to act as radiosensitizer in tumor treatment.",
keywords = "Brain tumor, COX-2 inhibition, Radiosensitization",
author = "P. Sminia and G. Kuipers and A. Geldof and V. Lafleur and B. Slotman",
year = "2005",
month = "10",
day = "1",
doi = "10.1016/S0753-3322(05)80044-7",
language = "English",
volume = "59",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "SUPPL. 2",

}

COX-2 inhibitors act as radiosensitizer in tumor treatment. / Sminia, P.; Kuipers, G.; Geldof, A.; Lafleur, V.; Slotman, B.

In: Biomedicine and Pharmacotherapy, Vol. 59, No. SUPPL. 2, 01.10.2005.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - COX-2 inhibitors act as radiosensitizer in tumor treatment

AU - Sminia, P.

AU - Kuipers, G.

AU - Geldof, A.

AU - Lafleur, V.

AU - Slotman, B.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Since cyclooxygenase-2 (COX-2) is overexpressed in malignant tissues, the COX-2 mediated signaling pathway has been recognized as potential target for therapeutic intervention. In most human tumors, COX-2 overexpression has been associated with tumor aggressiveness and poor clinical outcome. In vitro studies show inhibition of cell proliferation by selective COX-2 inhibitors alone, and enhancement of the response to irradiation. In vivo experimental reports demonstrate enhanced tumor response and impediment of tumor neovascularization following radiotherapy combined with COX-2 inhibition. Clinical studies on the combination of irradiation with COX-2 inhibitors are emerging. Taken together, the perspective for the combined approach of radiotherapy with COX-2 inhibition yields clinical significance since preclinical data demonstrate selective COX-2 inhibitors to act as radiosensitizer in tumor treatment.

AB - Since cyclooxygenase-2 (COX-2) is overexpressed in malignant tissues, the COX-2 mediated signaling pathway has been recognized as potential target for therapeutic intervention. In most human tumors, COX-2 overexpression has been associated with tumor aggressiveness and poor clinical outcome. In vitro studies show inhibition of cell proliferation by selective COX-2 inhibitors alone, and enhancement of the response to irradiation. In vivo experimental reports demonstrate enhanced tumor response and impediment of tumor neovascularization following radiotherapy combined with COX-2 inhibition. Clinical studies on the combination of irradiation with COX-2 inhibitors are emerging. Taken together, the perspective for the combined approach of radiotherapy with COX-2 inhibition yields clinical significance since preclinical data demonstrate selective COX-2 inhibitors to act as radiosensitizer in tumor treatment.

KW - Brain tumor

KW - COX-2 inhibition

KW - Radiosensitization

UR - http://www.scopus.com/inward/record.url?scp=27144462431&partnerID=8YFLogxK

U2 - 10.1016/S0753-3322(05)80044-7

DO - 10.1016/S0753-3322(05)80044-7

M3 - Article

VL - 59

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - SUPPL. 2

ER -